High-Dose Ipilimumab and High-Dose Interleukin-2 for Patients With Advanced Melanoma

High-dose ipilimumab (IPI) and high-dose interleukin-2 (IL-2) are approved agents for metastatic melanoma, but the efficacy and safety of the combination are unknown. The objective of this study was to evaluate the feasibility, safety, and efficacy of combination high-dose IPI and high-dose IL-2 in...

Descripción completa

Detalles Bibliográficos
Autores principales: Silk, Ann W., Kaufman, Howard L., Curti, Brendan, Mehnert, Janice M., Margolin, Kim, McDermott, David, Clark, Joseph, Newman, Jenna, Bommareddy, Praveen K., Denzin, Lisa, Najmi, Saltanat, Haider, Azra, Shih, Weichung, Kane, Michael P., Zloza, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965158/
https://www.ncbi.nlm.nih.gov/pubmed/31998643
http://dx.doi.org/10.3389/fonc.2019.01483

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6965158/
https://www.ncbi.nlm.nih.gov/pubmed/31998643
http://dx.doi.org/10.3389/fonc.2019.01483

Ejemplares similares